课题基金 / 基金详情

Mechanisms of initation of skeletal mineralization

Mechanisms of initation of skeletal mineralization
骨骼矿化的引发机制
批准号:
7210171
负责人:
JOSE LUIS MILLAN
金额:
$36.6万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-09-15 至 2010-08-31

项目摘要

项目成果

JOSE LUIS MILLAN的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):软骨和骨的矿化通过一系列物理化学和生物化学过程发生,这些过程共同促进羟基磷灰石在细胞外基质(ECM)的特定区域沉积。实验证据表明,羟基磷灰石(HA)晶体沿着胶原纤维在ECM中的存在,也在成软骨细胞和成骨细胞衍生的基质囊泡(MV)的内腔中。我们的工作模型是骨矿化首先在MV内腔内启动。在第二步中,HA晶体生长超出MV的范围,并暴露于细胞外环境,在那里它们继续沿着胶原原纤维增殖。我们最近的数据表明,组织非特异性碱性磷酸酶(TNAP)在限制细胞外无机焦磷酸盐(PPi)(矿化抑制剂)的浓度以维持正常骨矿化所允许的Pi/PPj比率方面起着至关重要的作用。使用多种单基因和双基因敲除实验,我们发现TNAP功能缺陷的小鼠,即,Akp 2-/-小鼠由于细胞外PPj浓度增加引起的MV外HA晶体传播停滞而显示骨软化。然而,在MV内部,HA晶体仍然存在于Akp 2-/-小鼠中。我们还发现,TNAP和I型胶原的共表达对于引起任何ECM的矿化是必需的,这表明HA晶体在骨ECM中的增殖密切依赖于I型胶原的存在。但是为什么Akp 2-/-小鼠出生时就有矿化的骨骼,并且在它们的MV中有HA晶体呢?我们假设,一个新发现的可溶性磷酸酶称为PHOSPHO 1,存在于MV中,是负责增加的MV内的局部浓度的Pi改变Pi/PPi的比例,有利于HA晶种的沉淀。我们将通过影响MV介导的矿化的第一步和第二步,使用遗传和药理学方法来测试这一假设。在实验上,我们将表征与Akp 2-/-小鼠相比Phospho 1表达缺陷小鼠的矿化异常和相关代谢变化,并评估Phospho 1和Akp 2基因同时失活对骨骼矿化的影响。我们还将研究消融或抑制PHOSPHO 1和/或TNAP活性对成骨细胞衍生的MV在体外引发和传播钙化的能力的影响。我们的工作将为正常骨矿化的机制提供基本的见解。我们的项目还将产生有价值的工具和试剂,这将有助于未来的研究,旨在了解各种骨矿化和软组织骨化异常的发展,包括一些重大公共卫生问题的疾病,例如,骨关节炎骨质疏松和动脉钙化
英文摘要
DESCRIPTION (provided by applicant): Mineralization of cartilage and bone occurs by a series of physicochemical and biochemical processes that together facilitate the deposition of hydroxyapatite in specific areas of the extracellular matrix (ECM). Experimental evidence has pointed to the presence of hydroxyapatite (HA) crystals along collagen fibrils in the ECM and also within the lumen of chondroblast- and osteoblast-derived matrix vesicles (MVs). Our working model is that bone mineralization is first initiated within the lumen of MVs. In a second step, HA crystals grow beyond the confines of the MVs and become exposed to the extracellular milieu where they continue to propagate along collagen fibrils. Our recent data have indicated that tissue-nonspecific alkaline phosphatase (TNAP) plays a crucial role in restricting the concentration of extracellular inorganic pyrophosphate (PPi), a mineralization inhibitor, to maintain a Pi/PPj ratio permissive for normal bone mineralization. Using a variety of single and double gene knockout experiments we have found that mice deficient in TNAP function, i.e., Akp2-/- mice, display osteomalacia due to an arrest in the propagation of HA crystals outside the MVs caused by an increase in extracellular PPj concentrations. Inside the MVs, however, HA crystals are still present in Akp2-/- mice. We have also found that the co-expression of TNAP and type I collagen is necessary to cause mineralization of any ECM indicating that propagation of HA crystals in the bone ECM is intimately dependent on the presence of type I collagen. But why are Akp2-/- mice born with a mineralized skeleton and have HA crystals in their MVs? We hypothesize that a newly identified soluble phosphatase called PHOSPHO1, present in the MVs, is responsible for increasing the local concentration of Pi inside the MVs to change the Pi/PPi ratio to favor precipitation of HA seed crystals. We will test this hypothesis by affecting the first and second steps of MV-mediated mineralization using a genetic and pharmacological approach. Experimentally we will characterize the mineralization abnormalities and related metabolic changes in mice deficient in Phospho1 expression compared to Akp2-/- mice and assess the effect of the simultaneous inactivation of the Phospho1 and Akp2 genes on skeletal mineralization. We will also study the effects of ablating or inhibiting PHOSPHO1 and/or TNAP activity on the ability of osteoblast- derived MVs to initiate and propagate calcification in vitro. Our work will provide fundamental insights into the mechanisms of normal bone mineralization. Our project will also produce valuable tools and reagents that will facilitate future studies aimed at understanding the development of diverse bone mineralization and soft tissue ossification abnormalities that include some diseases of great public health concern, e.g., osteoarthritis, osteoporosis, and arterial calcification.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Project 4 - Mechanisms of pyrophosphate dysregulation
  • 批准号:
    10628931
  • 项目类别:
  • 资助金额:
    $68.44万
  • 财政年份:
    2023
  • 负责人:
    JOSE LUIS MILLAN
  • 依托单位:
Exploratory Therapy for the Skeletal/Dental Phenotype in PHOSPHO1 Deficiency
Exploratory Therapy for the Skeletal/Dental Phenotype in PHOSPHO1 Deficiency
Leads and Target Validation for Vascular Calcification in Chronic Kidney Disease
海外基金